Targeted delivery of DOX by transferrin conjugated DSPE-PEG nanoparticles in leukemia therapy
Source abstract
Abstract
In this study, transferrin (Tf) conjugated distearoyl phosphatidylethanolamine-polyethylene glycol (DSPE-PEG) nanoparticles (DPT) was successfully prepared to deliver doxorubicin (DOX) to improve the chemotherapy efficacy of K562 leukemia cells. The results show that DPT were nanosized and presented spherical shaped particles, and the average particle size is about 80 nm. The DOX encapsulation efficiency of DPT was >70%. These nanoparticles could release DOX in the acid nucleus and facilitate the delivery of DOX after endocytosis. In addition, DPT is more targeted to K562 cancer cells than DSPE-PEG nanoparticles (DP). To be specific, the cytotoxic effect of DPT on cancer cells was significantly higher than that of DP, indicating that the tf modified nanoparticle system has better targeting efficiency. In summary, the results clearly show that the targeting of leukemia cells by the Tf -coupled nanoparticle system may pave the way for successful treatment of leukemia.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Dendrimers and Hyperbranched Polymers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Hematology, Institute of Hematology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China;
Department of Traditional Chinese Medicine, Hebei General Hospital, Hebei, China;
Department of Prevention and Healthcare, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China;
Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Guangdong Provincial Engineering and Technological Research Center for Drug Carrier Development, Department of Biomedical Engineering, Jinan University, Guangzhou, China
References (36)
Show source-provided references
1. 10.1016/j.leukres.2009.01.02410.1016/j.leukres.2009.01.024 ↗
2. 10.3322/caac.2013810.3322/caac.20138 ↗
3. 10.1200/JCO.1986.4.3.42510.1200/JCO.1986.4.3.425 ↗
4. 10.1200/JCO.2008.16.025910.1200/JCO.2008.16.0259 ↗
5. 10.1016/j.addr.2013.07.01210.1016/j.addr.2013.07.012 ↗
6. 10.1038/s41598-019-41866-y10.1038/s41598-019-41866-y ↗
7. 10.1016/j.ejpb.2006.11.00910.1016/j.ejpb.2006.11.009 ↗
8. 10.1016/j.jconrel.2007.12.01710.1016/j.jconrel.2007.12.017 ↗
9. 10.1166/jnn.2007.1811210.1166/jnn.2007.18112 ↗
10. 10.1166/jnn.2007.00710.1166/jnn.2007.007 ↗
11. 10.1021/mp900205r10.1021/mp900205r ↗
12. 10.1016/j.biomaterials.2012.08.07210.1016/j.biomaterials.2012.08.072 ↗
13. 10.1007/978-1-4939-3112-5_1310.1007/978-1-4939-3112-5_13 ↗
14. 10.1016/j.ejps.2009.04.00810.1016/j.ejps.2009.04.008 ↗
15. 10.1021/acsami.6b0916310.1021/acsami.6b09163 ↗
16. 10.1016/j.colsurfb.2015.08.03910.1016/j.colsurfb.2015.08.039 ↗
17. Guo L. · Int. J. Nanomedicine. · 2015 · 10 · 4535
18. 10.1016/j.actbio.2016.07.00610.1016/j.actbio.2016.07.006 ↗
19. 10.1016/j.clim.2006.06.01010.1016/j.clim.2006.06.010 ↗
20. 10.1016/j.ijpharm.2010.10.05310.1016/j.ijpharm.2010.10.053 ↗
21. 10.1016/j.ejps.2006.07.00410.1016/j.ejps.2006.07.004 ↗
22. 10.1016/j.clim.2006.06.00610.1016/j.clim.2006.06.006 ↗
23. 10.1158/1078-0432.CCR-12-319110.1158/1078-0432.CCR-12-3191 ↗
24. 10.1021/acsami.5b0326310.1021/acsami.5b03263 ↗
25. 10.1039/c3nr00357d10.1039/c3nr00357d ↗
26. 10.1021/bm401819x10.1021/bm401819x ↗
27. 10.1016/j.carbpol.2013.11.00910.1016/j.carbpol.2013.11.009 ↗
28. 10.2147/IJN.S8492710.2147/IJN.S84927 ↗
29. 10.1016/j.jconrel.2015.04.02610.1016/j.jconrel.2015.04.026 ↗
30. 10.1080/1061186090304662810.1080/10611860903046628 ↗
31. 10.1021/bc060077y10.1021/bc060077y ↗
32. 10.1002/smll.20070049310.1002/smll.200700493 ↗
33. 10.3892/ol.2014.284010.3892/ol.2014.2840 ↗
34. 10.1016/j.jconrel.2017.04.04310.1016/j.jconrel.2017.04.043 ↗
35. 10.1016/j.biopha.2016.05.04610.1016/j.biopha.2016.05.046 ↗
36. 10.1016/j.biomaterials.2008.12.07510.1016/j.biomaterials.2008.12.075 ↗